Preclinical studies have demonstrated that atirmociclib provides more effective CDK4 suppression and stronger tumour growth inhibition in HR+/HER2− breast cancer while markedly reducing its impact on hematopoietic stem and progenitor cells compared to dual CDK4/6 inhibitors [32]. The gene discussed is CDK4; the disease is neoplasm.